Pathogens

Monkeypox virus
(enveloped virus)

The Mpox virus (Orthopoxvirus simiae, genus Orthopoxvirus; enveloped virus) was initially referred to as monkeypox virus. Since November 28, 2022, however, the WHO has recommended the term Mpox for the disease formerly known as monkeypox [1]. The virus has also been officially renamed Mpox virus.

Discovery and occurrence

The Mpox virus was discovered in captive macaques in 1958. Human disease was first described in 1970 in the Democratic Republic of Congo and sporadically in other Central and West African countries throughout the 1970s [2]. Reports from non-endemic countries were rare until 2022. Since May 2022, there has been a continuing worldwide outbreak, also affecting non-endemic countries such as Germany [3,4]. The increasing spread in humans is attributed to the global decline in population immunity following the cessation of smallpox vaccination [2].
Enveloped viruses
These viruses have glycoproteins on their envelope, which are potential targets for external influences.

Disease and symptoms

The disease caused by the Mpox virus is known as Mpox (formerly monkeypox). The average incubation period is reported to be 5–21 days, although shorter incubation periods of 1–4 days have been reported since the worldwide outbreak. The non-specific symptoms of Mpox initially include fever, headache, muscle and back pain, and swollen lymph nodes. The typical skin changes that give the disease its name usually only appear later on and are found primarily on the face, palms and soles of the feet, as well as in the mouth, urogenital and anal areas, and eyes. Over the course of the disease (usually 2–4 weeks), the rash changes from a spot to a pustule, later crusting over and falling off. The disease caused by the clade IIb virus strain that predominantly circulates in non-endemic countries is usually mild and self-limiting in humans. However, complications such as bacterial superinfections are possible [2-5].

Transmission

Mpox can be transmitted both from animals to humans and from person to person. Human-to-human transmission, which normally requires close physical contact, has only been a focus since 2022. The virus primarily uses tiny skin lesions or mucous membranes (eyes, mouth, nose, genitals) to enter the body. Particularly high virus concentrations are found in the typical pustules, but other bodily fluids (secretions and excretions) probably also contain viruses. While droplet infection is theoretically conceivable, it probably only occurs with prolonged face-to-face contact. Furthermore, the virus can be transmitted from pregnant women to the unborn fetus or to the child during birth [3-5].

Transmission via animals is possible through contact with infected animals or contaminated animal products, e.g. through bites, close handling, contact with secretions or excretions, consumption of contaminated, insufficiently cooked meat, etc. Even though monkeys can become infected, the presumed wild animal reservoir for the Mpox virus is not monkeys, but mainly rodents [3-5].

Hygienic measures

To contain the further spread of Mpox, the population should be informed about preventive behavioral measures. These include, for example, avoiding close contact with (suspected) infected individuals. Also, laundry items such as towels or bed linen should not be shared. Vaccination against human smallpox (variola) offers a certain degree of protection against Mpox and can be administered under specific indications. Furthermore, it is important to quickly identify new cases [3-5]. Individuals with confirmed disease should isolate themselves at home until general symptoms have subsided and scabs and crusts have completely healed or fallen off. Monitoring of asymptomatic contacts of infected individuals is recommended [3,5].

To prevent the transmission of Mpox in healthcare facilities, proper hand hygiene with a hand disinfectant with at least limited virucidal activity and appropriate glove changes are recommended. Employees who directly care for sick patients should also protect themselves with FFP2 masks and personal protective equipment. Disinfectants with at least a limited virucidal spectrum of activity should also be used for surface disinfection. Since the virus can persist for a long time, contact times must be strictly observed [5].

Current situation

According to the WHO, 29,607 cases had been reported from 47 countries by April 14, 2025. By the end of 2022, these cases exclusively concerned the strain circulating in West Africa (clade IIb), which causes less severe cases than the Central African strain (clade I/Ib) [6]. In July 2022, the WHO declared the Mpox outbreak a Public Health Emergency of International Concern (PHEIC) for the first time. Given that a new virus strain, Clade Ib, is spreading in Central Africa, the WHO renewed its PHEIC assessment on August 14, 2024 [7]. At the end of April 2025, a case of clade I was reported in Sweden for the first time outside of Africa [8].

The risk from clade I for the European region is currently considered low/very low [9].

Zoonotic risk

The current mpox outbreak is a classic example of a zoonotic disease, as the mpox virus originally only appeared in wild animals. However, since humans are increasingly intruding and destroying the natural habitat of wild animals, zoonoses are becoming an increasing threat to humans [10].

Required spectrum of activity of disinfectants

Since the Mpox virus is an enveloped virus, disinfectants (for both hands and surfaces) that have at least a limited virucidal spectrum of activity are recommended [6].

Click here to find products with activity against enveloped viruses.

Sources:

  1. World Health Organization (2022) News release: https://www.who.int/news/item/28-11-2022-who-recommends-new-name-for-monkeypox-disease (accessed on October 9, 2025)
  2. Nitsche A et al. (2019). Infektionen des Menschen mit Affenpocken [Human monkeypox]. Flugmedizin Tropenmedizin Reisemedizin 26: 18–24. https://edoc.rki.de/bitstream/handle/176904/9723/2019%20Affenpocken_final_revised_submitt.pdf?sequence=3&isAllowed=y
  3. Health Organization (2024) Fact sheet: Mpox. https://www.who.int/news-room/fact-sheets/detail/mpox (accessed on October 9, 2025)
  4. Centers for Disease Control and Prevention (2023) https://stacks.cdc.gov/view/cdc/123270/cdc_123270_DS1.pdf (accessed on October 9, 2025)
  5. Centers for Disease Control and Prevention (2025) Infection Prevention and Control of Mpox in Healthcare Settings. https://www.cdc.gov/monkeypox/hcp/infection-control/healthcare-settings.html (accessed on October 9, 2025)
  6. World Health Organization and European Centre for Disease Prevention and Control (2025) Joint ECDC-WHO Regional Office for Europe Mpox Surveillance Bulletin. https://monkeypoxreport.ecdc.europa.eu/ (accessed on October 9, 2025)
  7. World Health Organization (2024) https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern (accessed on October 9, 2025)
  8. Treutiger CJ et al. (2024) First case of mpox with monkeypox virus clade Ib outside Africa in a returning traveller, Sweden, August 2024: public health measures. Euro Surveill 29: 2400740. https://doi.org/10.2807/1560-7917European Centre for Disease Prevention and Control (2025) https://www.ecdc.europa.eu/sites/default/files/documents/2025-WCP-0054%20Final.pdf (accessed on October 9, 2025)
  9. Esposito MM et al. (2023) The Impact of Human Activities on Zoonotic Infection Transmissions. Animals (Basel) 13: 1646. https://doi.org/10.3390/ani13101646

This might also interest you